Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status-;according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

Evofem inks women’s health deal; AusperBio brings in $37M

Plus, news about Enveric, Aries Science, LENZ, MediWound and Destiny Pharma: Evofem acquires antimicrobial: The contraceptive maker is buying Lupin’s US … Sign up to

July 16, 2024

Creativity camp boosts well-being in teens with depression

Published in Child Psychiatry and Human Development, a research team led by the University of Minnesota Medical School found that Creativity Camp, a two-week arts

November 20, 2024

Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing

Nvelop Therapeutics launched Tuesday with $100 million in seed funding to advance research from the gene editing pioneers David Liu and Keith Joung, as they

April 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.